FY2025 EPS Estimates for BeiGene, Ltd. (NASDAQ:BGNE) Decreased by SVB Leerink

BeiGene, Ltd. (NASDAQ:BGNE) – SVB Leerink decreased their FY2025 earnings per share (EPS) estimates for BeiGene in a report released on Friday, May 7th. SVB Leerink analyst A. Berens now forecasts that the company will earn $3.90 per share for the year, down from their previous forecast of $4.13.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings results on Friday, May 7th. The company reported $0.69 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.90) by $2.59. BeiGene had a negative net margin of 569.22% and a negative return on equity of 56.81%.

A number of other equities analysts also recently issued reports on the company. China Renaissance Securities began coverage on BeiGene in a research report on Monday, March 8th. They set a “buy” rating on the stock. Cowen boosted their target price on BeiGene from $348.00 to $429.00 and gave the stock an “outperform” rating in a report on Thursday, February 25th. Morgan Stanley cut their price target on BeiGene from $375.00 to $357.00 and set an “overweight” rating for the company in a report on Monday. Piper Sandler boosted their price objective on BeiGene from $185.00 to $190.00 in a research note on Tuesday, January 12th. Finally, Zacks Investment Research raised BeiGene from a “sell” rating to a “hold” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $316.56.

Shares of BGNE opened at $322.00 on Monday. The business’s 50-day moving average is $321.71 and its two-hundred day moving average is $306.33. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.64 and a current ratio of 7.69. The company has a market capitalization of $29.53 billion, a P/E ratio of -15.93 and a beta of 0.91. BeiGene has a fifty-two week low of $155.16 and a fifty-two week high of $388.97.

In other BeiGene news, COO Xiaobin Wu sold 6,715 shares of the company’s stock in a transaction on Monday, May 3rd. The stock was sold at an average price of $343.00, for a total transaction of $2,303,245.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CMO Jane Huang sold 1,500 shares of the firm’s stock in a transaction on Thursday, April 29th. The stock was sold at an average price of $354.92, for a total value of $532,380.00. Following the transaction, the chief marketing officer now owns 285,583 shares of the company’s stock, valued at $101,359,118.36. The disclosure for this sale can be found here. Insiders sold 9,715 shares of company stock worth $3,321,625 in the last ninety days. 9.00% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Parallel Advisors LLC grew its position in BeiGene by 35.0% in the 4th quarter. Parallel Advisors LLC now owns 135 shares of the company’s stock valued at $35,000 after acquiring an additional 35 shares in the last quarter. Signaturefd LLC boosted its stake in shares of BeiGene by 90.1% in the fourth quarter. Signaturefd LLC now owns 249 shares of the company’s stock valued at $64,000 after purchasing an additional 118 shares during the period. Marshall Wace North America L.P. acquired a new position in shares of BeiGene in the first quarter valued at approximately $76,000. Bedel Financial Consulting Inc. purchased a new stake in BeiGene during the 1st quarter worth approximately $122,000. Finally, Fieldpoint Private Securities LLC acquired a new stake in BeiGene during the 4th quarter worth approximately $130,000. 60.65% of the stock is currently owned by hedge funds and other institutional investors.

BeiGene Company Profile

BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Featured Article: Net Asset Value

Earnings History and Estimates for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.